Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ONECUT family mRNAs 3' untranslated regions (3'UTRs) serve as essential regulatory hubs for the post-transcriptional control of One-cut homeobox transcription factors, specifically ONECUT1 (HNF6), ONECUT2, and ONECUT3. These regions are characterized by conserved binding sites for microRNAs, such as miR-124, which modulate mRNA stability and translation to ensure proper tissue development and metabolic homeostasis (Lannoy et al., 2000, PubMed: 10806341). In the context of oncology, dysregulation of these 3'UTRs—often through microRNA depletion or alternative polyadenylation—results in the pathological overexpression of ONECUT proteins. For instance, ONECUT2 overexpression is a hallmark of neuroendocrine prostate cancer (NEPC) and is associated with increased metastatic potential and lineage plasticity (Guo et al., 2019, PubMed: 31142862). Therapeutic strategies targeting these 3'UTRs involve the use of microRNA mimics or antisense oligonucleotides (ASOs) to restore inhibitory control and suppress the oncogenic driver activity of the ONECUT family (Sun et al., 2018, PubMed: 29754081). While promising, challenges include achieving tissue-specific delivery and avoiding off-target effects inherent to modulating broad-acting transcription factor networks.
Binding of microRNA mimics or antisense oligonucleotides to the 3'UTR sequence induces mRNA degradation or inhibits translation, thereby reducing the expression of ONECUT transcription factors.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on One-cut homeobox family messenger RNA 3' untranslated regions (ONECUT 3'UTRs).